December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
All-oral regimen of selinexor/pomalidomide/low-dose dexamethasone appears to be highly active and have a manageable safety profile in patients with R/R MM after ≥ 2 previous therapies.